fluorine F 18 FP-R01-MG-F2

fluorine F 18 FP-R01-MG-F2 is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging. It consists of a cystine knot peptide (knottin) engineered to bind with high affinity to integrin αvβ6, a cell surface receptor overexpressed in several cancers, including pancreatic cancer, and in fibrotic diseases such as idiopathic pulmonary fibrosis. The peptide is radiolabeled with fluorine-18 via a fluoropropionate group. This tracer enables visualization of primary tumors and metastases by targeting integrin αvβ6 expression. Clinical studies have shown it to be safe and effective for detecting pancreatic cancer lesions and distant metastases, often outperforming standard PET tracers like 18F-FDG for certain metastatic sites[1][4][5][6]. It has also demonstrated uptake in the lungs of patients with idiopathic pulmonary fibrosis due to chronic overexpression of its target[6]. The drug was developed by Stanford University in collaboration with Pliant Therapeutics[3].

Other names

fluorine F 18 FP-R01-MG-F2